We are live on ! Find out more
STTK icon

Shattuck Labs

74 hedge funds and large institutions have $132M invested in Shattuck Labs in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 29 increasing their positions, 16 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 16

35% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 17

7% more funds holding

Funds holding: 6974 (+5)

5.6% more ownership

Funds ownership: 66.27%71.88% (+5.6%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

53% less capital invested

Capital invested by funds: $281M → $132M (-$149M)

78% less call options, than puts

Call options by funds: $24K | Put options by funds: $109K

Holders
74
Holders Change
+5
Holders Change %
+7.25%
% of All Funds
1.07%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
23
Increased
29
Reduced
16
Closed
17
Calls
$24K
Puts
$109K
Net Calls
-$85K
Net Calls Change
+$291K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$27.5M +$93.4K +11,483 +0.2%
RG
2
Redmile Group
California
$21.7M
PM
3
Prosight Management
Texas
$18M +$7.68M +945,000 +25%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$10.6M +$3.05M +375,000 +16%
BlackRock
5
BlackRock
New York
$9.55M +$15.8M +1,944,964 +367%
Vanguard Group
6
Vanguard Group
Pennsylvania
$8.89M +$3.93M +483,074 +27%
Franklin Resources
7
Franklin Resources
California
$6.06M -$750K -92,231 -6%
CEI
8
Clark Estates Inc
New York
$5.7M
Geode Capital Management
9
Geode Capital Management
Massachusetts
$3.49M +$3.71M +456,331 +102%
State Street
10
State Street
Massachusetts
$2.74M +$4.51M +554,913 +356%
PA
11
Pinnacle Associates
New York
$2.31M +$636K +78,177 +15%
TPC
12
Takeda Pharmaceutical Company
Japan
$1.99M -$8.01M -985,442 -66%
Renaissance Technologies
13
Renaissance Technologies
New York
$1.51M +$1.45M +177,910 +83%
Two Sigma Investments
14
Two Sigma Investments
New York
$885K +$854K +105,069 +85%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$857K +$1.22M +150,340 +210%
Morgan Stanley
16
Morgan Stanley
New York
$848K +$958K +117,799 +115%
Citadel Advisors
17
Citadel Advisors
Florida
$753K +$1.56M +191,851 +5,914%
RWM
18
Ritholtz Wealth Management
New York
$550K +$423K +52,000 +57%
Pathstone Holdings
19
Pathstone Holdings
New Jersey
$485K -$179 -22 -0%
Connor, Clark & Lunn Investment Management (CC&L)
20
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$478K +$377K +46,397 +60%
Charles Schwab
21
Charles Schwab
California
$467K +$814K +100,078 +479%
Northern Trust
22
Northern Trust
Illinois
$415K +$93.9K +11,546 +12%
Millennium Management
23
Millennium Management
New York
$374K -$4.19M -515,472 -84%
Goldman Sachs
24
Goldman Sachs
New York
$361K -$1.34M -164,640 -64%
LFWA
25
LBJ Family Wealth Advisors
Texas
$317K +$668K +82,177 New

STTK Hedge Fund Activity: Q2 2024 in Review

74 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Shattuck Labs (STTK) for Q2 2024, worth a combined $132M — down 53% from $281M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new STTK positions and 17 closed out — a net gain of 6 holders — while 29 added to existing stakes and 16 trimmed.

The largest buyer was BlackRock, adding an estimated $15.8M. The largest seller was Takeda Pharmaceutical Company, cutting an estimated $8.01M.

  • 74 institutional investors held Shattuck Labs (STTK) as of Q2 2024, up from 69 in Q1 2024.
  • Funds reported $132M of Shattuck Labs stock for Q2 2024, down 53% quarter-over-quarter.
  • 23 funds opened new Shattuck Labs positions in Q2 2024 and 17 closed out, a net change of +6 holders.
  • The largest Shattuck Labs buyer in Q2 2024 was BlackRock, an estimated $15.8M added.
  • The largest Shattuck Labs seller in Q2 2024 was Takeda Pharmaceutical Company, an estimated $8.01M sold.

Based on aggregated 13F filings for Q2 2024.